Randomized, Double-Blind Study of Ciprofloxacin and Cefuroxime Axetil for Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis

In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil. Clinical and microbiological...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1998-10, Vol.27 (4), p.722-729
Main Authors: Chodosh, Sanford, McCarty, James, Farkas, Stephen, Drehobl, Margaret, Tosiello, Robert, Shan, Michael, Aneiro, Lynn, Kowalsky, Steven
Format: Article
Language:English
Subjects:
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antimicrobials
Asthma
Biological and medical sciences
Chronic bronchitis
Chronic obstructive pulmonary disease
Clinical Articles
Investigational drugs
Investigational therapies
Medical sciences
Pathogens
Pharmacology. Drug treatments
Relapse
Respiratory tract infections
Sputum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil. Clinical and microbiological responses at the end of therapy were secondary efficacy variables. Outpatients randomly received either ciprofloxacin or cefuroxime axetil (500 mg twice a day for 14 days). Three hundred seven patients with acute exacerbations of chronic bronchitis were enrolled, of whom 208 had an exacerbation due to a bacterial pathogen. Clinical resolution at the end of ciprofloxacin and cefuroxime axetil therapy for patients for whom efficacy could be evaluated was 93% and 90%, respectively. Bacteriologic eradication rates were statistically higher for ciprofloxacin recipients (96% [89 of 93]) than for cefuroxime axetil recipients (82% [80 of 97]) (P < .01). The median infection-free interval was 146 days for ciprofloxacin recipients vs. 178 days for cefuroxime axetil recipients (P = .37). In conclusion, ciprofloxacin was associated with an infection-free interval and clinical response that were similar to those associated with cefuroxime axetil, but the bacteriologic eradication rate associated with ciprofloxacin was statistically significantly higher than that associated with cefuroxime axetil.
ISSN:1058-4838
1537-6591
DOI:10.1086/514930